Investigating the difference between infliximab treatment injected into a vein and injected under the skin in patients with inflammatory bowel disease and inflammatory arthritis already established on infliximab injected into a vei

Phase 4

• Conditions: lcerative colitis, crohn's disease, rheumatoid arthritis, psoriatic arthritis, or ankylosis spondylitis; Not Applicable; Ulcerative colitis, Crohn's disease, rheumatoid arthritis, psoriatic arthritis, or ankylosis spondylitis

• Registration Number: ISRCTN13323475
• Lead Sponsor: niversity Hospital Southampton NHS Foundation Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-02-10
• Last Update Posted: 1 February 2022
• Study Completion: 2022-05-02

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Confirmed diagnosis of Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, and/or ankylosis spondylitis
2. Established on IV infliximab (>4 doses) prior to study enrolment
3. Anticipated to remain on infliximab for the duration of the study
4. Last dose of IV infliximab received <8 weeks ago
5. Able to comply with study requirements
6. Able to provide informed consent
7. Aged =18 years

Exclusion Criteria

1. Allergic to any of the known excipients of infliximab
2. Scheduled for a surgical procedure or planned hospitalisation within 6 months of enrolment
3. Not anticipated to remain on infliximab for >6 months after enrolment
4. Pregnant or lactating

Study & Design

• Study Type: Interventional
• Study Design: Not specified